Arbaclofen Placarbil
- Generic Name
- Arbaclofen Placarbil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H26ClNO6
- CAS Number
- 847353-30-4
- Unique Ingredient Identifier
- W89H91R7VX
- Background
Arbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.
Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned by XenoPort in 2011 for the treatment of GERD. On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis.
- Indication
Investigated for the treatment of spasticity in multiple sclerosis, acute back spasms, and GERD.
- Associated Conditions
- -
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.